GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Valuation Rank

Brainstorm Cell Therapeutics (FRA:GHDN) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Brainstorm Cell Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Valuation Rank
Comparable Companies
GNPX SEEL MYMD VBIV PHGE LEXX HEPA NRXS MBIO APM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
BCLI:USA GHDN:Germany
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Website
https://www.brainstorm-cell.com
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.